Investment Thesis
Myriad Genetics demonstrates a structurally sound business model with 68.7% gross margins, but faces severe operational challenges with negative operating income, unprofitable net results, and significant free cash flow deterioration (-$58.0M). With revenue declining YoY and an annual cash burn exceeding available liquidity runway, the company requires urgent operational restructuring and cannot sustain current CapEx levels without fundamental profitability improvements.
Strengths
- Strong gross margin of 68.7% indicates viable underlying product economics and pricing power
- Conservative debt structure with 0.36x Debt/Equity ratio and $124.4M cash provides financial flexibility
- Solid liquidity position with 2.40x current ratio and 2.19x quick ratio supports near-term obligations
Risks
- Company is unprofitable at operating level (-15.3% margin) and net level (-17.0% margin) with deteriorating ROE (-10.1%) and ROA (-5.1%)
- Negative free cash flow of -$58.0M combined with declining revenue creates unsustainable burn trajectory with approximately 2-year cash runway at current rate
- Operating expenses exceed revenue generation capabilities despite strong gross margins, suggesting structural cost issues or failed investment thesis in current product mix
Key Metrics to Watch
- Operating cash flow inflection and path to cash flow breakeven
- Revenue stabilization or growth acceleration to justify continued capital expenditures
- Operating expense rationalization and progress toward operating profitability
Financial Metrics
Revenue
200.4M
Net Income
-34.1M
EPS (Diluted)
$-0.36
Free Cash Flow
-58.0M
Total Assets
673.7M
Cash
124.4M
Profitability Ratios
Gross Margin
68.7%
Operating Margin
-15.3%
Net Margin
-17.0%
ROE
-10.1%
ROA
-5.1%
FCF Margin
-28.9%
Balance Sheet & Liquidity
Current Ratio
2.40x
Quick Ratio
2.19x
Debt/Equity
0.36x
Debt/Assets
49.9%
Interest Coverage
-61.40x
Long-term Debt
120.3M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-07T09:54:46.896208 |
Data as of: 2026-03-31 |
Powered by Claude AI